References
- Alfredo García-Arieta CS, Lima Santos GM, et al. A survey of the regulatory requirements for the acceptance of foreign comparator products by participating regulators and organizations of the International Generic Drug Regulators Programme. J Pharm Pharm Sci. 2019;22:28–36.
- Liew KB, Peh KK, Loh GO, et al. Three ways crossover bioequivalence study of cephalexin in healthy Malay volunteers. Drug Dev Ind Pharm. 2014;40:1156–1162.
- Yang B, Wu C, Ji B, et al. Virtual population pharmacokinetic using physiologically based pharmacokinetic model for evaluating bioequivalence of oral lacidipine formulations in dogs. Asian J Pharm Sci. 2017;12:98–104.
- US Food and Drug Administration (FDA). Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System Guidance for Industry [updated 2017 Dec 22; cited 2019 Mar 20]. Available from: https://www.fda.gov/RegulatoryInformation/Guidances/default.htm.
- Cook JA, Davit BM, Polli JE. Impact of biopharmaceutics classification system-based biowaivers. Mol Pharmaceutics. 2010;7:1539.
- Mehta MU, Uppoor RS, Conner DP, et al. Impact of the US FDA “Biopharmaceutics Classification System” (BCS) guidance on global drug development. Mol Pharmaceutics. 2017;14:4334–4338.
- Vaidhyanathan S, Wang X, Crison J, et al. Bioequivalence comparison of pediatric Dasatinib formulations and elucidation of absorption mechanisms through integrated PBPK modeling. J Pharm Sci. 2019;108:741–749.
- Kortejärvi H, Urtti A, Yliperttula M. Pharmacokinetic simulation of biowaiver criteria: the effects of gastric emptying, dissolution, absorption and elimination rates. Eur J Pharm Sci. 2007;30:155–166.
- Zaid AN, Shraim N, Radwan A. Does GastroPlus support similarity and dissimilarity factors of in vitro-in vivo prediction in biowaiver studies? A lower strength amlodipine as a model drug. Drug Res (Stuttg). 2018;68:625–630.
- Wu C, Kou L, Ma P, et al. Interspecies prediction of oral pharmacokinetics of different lacidipine formulations from dogs to human: physiologically based pharmacokinetic modelling combined with biorelevant dissolution. RSC Adv. 2015;5:19844–19852.
- Chakraborty S, Yadav L, Aggarwal D. Prediction of in vivo drug performance using in vitro dissolution coupled with STELLA: a study with selected drug products. Drug Dev Ind Pharm. 2015;41:1667–1673.
- Heimbach T, Suarez-Sharp S, Kakhi M, et al. Dissolution and translational modeling strategies toward establishing an In Vitro-In Vivo Link–a workshop summary report. AAPS J. 2019;21:29.
- Shah N, Sharma OP, Mehta T, et al. Design of experiment approach for formulating multi-unit colon-targeted drug delivery system: in vitro and in vivo studies. Drug Dev Ind Pharm. 2016;42:825–835.
- Rediguieri CF, Porta V, G. Nunes DS, et al. Biowaiver monographs for immediate release solid oral dosage forms: metronidazole. J Pharm Sci. 2011;100:1618–1627.
- National Medical Products Administration (NMPA); [cited 2019 Mar 28]. Available from: http://www.nmpa.gov.cn/WS04/CL2182/228233.html.
- Shi C, Du J, Wang M, et al. Similarity investigation on dissolution curves of metronidazole tablets from different manufacturers. Her Med. 2017;36:917–922.
- Reddy NH, Patnala S, Lobenberg R, et al. In vitro dissolution of generic immediate-release solid oral dosage forms containing BCS class I drugs: comparative assessment of metronidazole, zidovudine, and amoxicillin versus relevant comparator pharmaceutical products in South Africa and India. AAPS PharmSciTech. 2014;15:1076–1086.
- Alves A, Aquino T, Neto J, et al. Bioequivalence between two metronidazole formulations. Lat Am J Pharm. 2007;26:266–269.
- Emil Gatchev MB, de Mey C. Bioequivalence of a novel oral metronidazole formulation. Arzneim-Forsch. 2006;56:612–616.
- de Freitas Silva M, Schramm SG, Kano EK, et al. Metronidazole immediate release formulations: a fasting randomized open-label crossover bioequivalence study in healthy volunteers. Arzneim-Forsch. 2012;62:490–495.
- Ezzeldin E, El-Nahhas TM. New analytical method for the determination of metronidazole in human plasma: application to bioequivalence study. Trop J Pharm Res. 2013;11:799–805.
- Vanol PG, Sanyal M, Shah PA, et al. Quantification of metronidazole in human plasma using a highly sensitive and rugged LC-MS/MS method for a bioequivalence study. Biomed Chromatogr. 2018;32:e4242.
- Jaber E, Neda G, Hamed H, et al. A rapid and sensitive HPLC method for the analysis of metronidazole in human plasma application to single dose pharmacokinetic and bioequivalence studies. J Pharm Sci. 2006;14:15–21.
- Ogata H, Aoyagi N, Kaniwa N, et al. BIavailability of metronidazole from sugar-coated tablets in humans. I. Effect of gastric acidity and correlation with in vitro dissolution rate. Int J Pharm. 1985;23:277–288.
- Idkaidek NM, Najib NM. Enhancement of oral absorption of metronidazole suspension in humans. Eur J Pharm Biopharm. 2000;50:213–216.
- Pharmaceuticals and Medical Devices Agency (pmda) [cited 2019 Mar 2]. Available from: http://www.pmda.go.jp/PmdaSearch/iyakuSearch/.
- Davis JL, Little D, Blikslager AT, et al. Mucosal permeability of water-soluble drugs in the equine jejunum: a preliminary investigation. J Vet Pharmacol Ther. 2006;29:379–385.
- Ogata H, Aoyagi N, Kaniwa N, et al. Bioavailability of metronidazole from sugar-coated tablets in humans. II. Evaluation of beagle dogs as an animal model. Int J Pharm. 1985;23:289–298.
- Mattila J, Mannisto PT, Mantyla R, et al. Comparative pharmacokinetics of metronidazole and tinidazole as influenced by administration route. Antimicrob Agents Ch. 1983;23:721–725.
- de CBC, Berto LA, Venancio PC, et al. Concentrations of metronidazole in human plasma and saliva after tablet or gel administration. J Pharm Pharmacol. 2014;66:40–47.